Pineda, BegoñaMartínez Pretel, Juan JoséSánchez Serrano, PalomaBoussios, StergiosRodrigo Faus, MaríaPérez Leal, MartínObrador, ElenaPerea, JavierPérez Fidalgo, José Alejandro2026-04-022026-04-022026Pineda, B., Martinez-Pretel, J. J., Sanchez- Serrano, P., Boussios, S., Rodrigo-Faus, M., Pérez-Leal, M., Obrador, E., Perea, J., & Perez-Fidalgo, J. A. (2026). Eprenetapopt in combination with carboplatin in high-grade ovarian and triple negative breast cancer cell lines with acquired resistance to olaparib. Frontiers in Oncology, 16, 1754873. https://doi.org/10.3389/fonc.2026.17548732234-943Xhttps://hdl.handle.net/11268/16994High-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC) frequently exhibit mutations in DNA damage response (DDR) genes, as BRCA1, BRCA2 and TP53, which are associated with chemotherapy sensitivity. Olaparib, a PARP inhibitor, provides the greatest clinical benefit as maintenance therapy in HGSOC—particularly in tumors with BRCA1/2 mutations or broader homologous recombination deficiency (HRD)—whereas benefit in HRD−negative disease is limited. Eprenetapopt (APR-246) restores wild-type p53 function in tumor cells with TP53 mutations. This study investigates the potential of combining eprenetapopt with carboplatin to overcome resistance to the PARP inhibitor (PARPi) olaparib in HGSOC and TNBC cell lines. Combining eprenetapopt with carboplatin shows promising preclinical efficacy by enhancing cytotoxicity in olaparib−resistant models and demonstrating synergistic interaction; these data support the combination as a potential strategy to mitigate PARPi resistance and carboplatin cross−resistance in TP53 mutant HGSOC and TNBC cell lines.engAttribution 4.0 Internationalhttps://creativecommons.org/licenses/by/4.0/Neoplasias de la MamaNeoplasias OváricasNeoplasias de la Mama Triple NegativasEprenetapopt in combination with carboplatin in high-grade ovarian and triple negative breast cancer cell lines with acquired resistance to olaparibjournal article10.3389/fonc.2026.1754873open accessCiencias médicasBiología celularBioquímicaGoal 3: Ensure healthy lives and promote well-being for all at all agesGoal 5: Achieve gender equality and empower all women and girlsGoal 9: Build resilient infrastructure, promote sustainable industrialization and foster innovation